Quarterly report pursuant to Section 13 or 15(d)

Statements of Cash Flows

Statements of Cash Flows
3 Months Ended
Mar. 31, 2016
USD ($)
Cash Flows From Operating Activities:  
Net loss $ (332,241)
Adjustments to reconcile net loss to net cash used in operating activities:  
Stock-based compensation 2,101
Changes in operating assets and liabilities:  
Accounts payable and accrued liabilities 40,213
Net Cash Used In Operating Activities (289,927)
Cash Flows From Investing Activities:  
Investment in note receivable - Moleculin, LLC (30,000)
Net Cash Used In Investing Activities (30,000)
Cash Flows From Financing Activities:  
Proceeds from stock issuance 386,499
Proceeds from convertible notes payable 165,000
Net Cash Provided By Financing Activities 551,499
Net change in cash and cash equivalents 231,572
Cash and cash equivalents, at beginning of period 28,091
Cash and cash equivalents, at end of period 259,663
Supplemental disclosures of cash flow information:  
Cash paid for interest 0
Cash paid for income taxes $ 0